• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study of tumor associated antigens recognized by human CD8^+ cytotoxic T lymphocytes

Research Project

Project/Area Number 12213134
Research Category

Grant-in-Aid for Scientific Research on Priority Areas

Allocation TypeSingle-year Grants
Review Section Biological Sciences
Research InstitutionKurume University School of Medicine

Principal Investigator

ITOH Kyogo  Kurume Univ.Sch.Med, Dep.Immunol., Professor, 医学部, 教授 (50125499)

Co-Investigator(Kenkyū-buntansha) YAGITA Hideo  Juntendou Univ.Sch.Med., Dep.Immunol., Associate Professor (30182306)
Project Period (FY) 2000 – 2004
Project Status Completed (Fiscal Year 2004)
Budget Amount *help
¥137,000,000 (Direct Cost: ¥137,000,000)
Fiscal Year 2004: ¥25,700,000 (Direct Cost: ¥25,700,000)
Fiscal Year 2003: ¥26,200,000 (Direct Cost: ¥26,200,000)
Fiscal Year 2002: ¥27,000,000 (Direct Cost: ¥27,000,000)
Fiscal Year 2001: ¥26,100,000 (Direct Cost: ¥26,100,000)
Fiscal Year 2000: ¥32,000,000 (Direct Cost: ¥32,000,000)
KeywordsGene / Tumor antigen / Peptide / Immunity / Cytotoxic T lymphocytes / Vaccine / Translational reearch / Personalized medicine / 拒絶抗原 / NK細胞 / がん / 抗原 / アポトーシス / 免疫療法
Research Abstract

Research outcome: We made considerable progress in the past five years to identify tumor associated antigens recognized by human CD8+ cytotoxic T lymphocytes (CTL) reactive to cancer cells with an HLA-class I restricted fashion. We have identified more than 100 different tumor-associated antigen genes, along with more than 200 epitopes encoded by these genes, from cDNA of epithelial cancer cells. The majority of these genes encode antigens preferentially expressed in proliferating cells, but not in normal cells at the protein level. These CTL epitope peptides are bound to HLA-A24,-A2 molecules, or those of HLA-A3 family that includes the allelic products of at least five common HLA-A alleles: A3, All, A31, A33, and A68.
Some of the peptides mentioned above were provided to phasel /phase II clinical trials as a regimen of personalized peptide vaccination in which pre-vaccination PBMCs were at first screened for their reactivity in vitro to each of the candidate peptides followed by in vi … More vo administration of only the CTL-directed peptides. Adverse effects in this regimen were local skin reactions at the injection sites, and thus this regimen was evaluated as well tolerable. Some types of advanced cancers were sensitive to the personalized peptide vaccination, and they are hormone-refractory prostate cancer, gastric cancer with scirrhous type, cervical cancer, and grade3/4 brain tumors. In contrast, the other cancers were not sensitive to the personalized peptide vaccination under the employed condition, and they are colon cancer, lung cancer, non-scirrhous gastric cancer, melanoma, and pancreatic cancer. It is of note that, in these patients, the overall survival of patients whose sera had increased levels of peptide-reactive IgG (n=60) was significantly more prolonged (p=0.0003) than those who did not (n=31), whereas none of the cellular responses correlated with overall survival. Because of extremely lower survival rate of these diseases, personalized peptide vaccination could be a new treatment modality for advanced anaplastic astrocytoma and glioblastoma. In conclusion, our basic and clinical studies conducted in the past five years could provide novel information in order to develop peptide-based specific immunotherapy for cancer patients. Less

Report

(6 results)
  • 2004 Annual Research Report   Final Research Report Summary
  • 2003 Annual Research Report
  • 2002 Annual Research Report
  • 2001 Annual Research Report
  • 2000 Annual Research Report
  • Research Products

    (102 results)

All 2005 2004 2003 2002 2001 2000 Other

All Journal Article (27 results) Book (1 results) Patent(Industrial Property Rights) (18 results) Publications (56 results)

  • [Journal Article] A unique gene having homology with the kinesin family member 18A encodes a tumor-associated antigen recognized by bytotoxic T lymphocytes from HLA-A2+ colon cancer patients.2005

    • Author(s)
      Shichijo S., Itoh K., et al.
    • Journal Title

      Eur. J. Cancer (印刷中)

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Immediate early response gene X-l, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte(CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients.2004

    • Author(s)
      Sasada T., Itoh, K., et al.
    • Journal Title

      Cancer Res 64

      Pages: 2882-2888

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.2004

    • Author(s)
      Harada M., Gohara R., Matsueda S., Muto A., Oda T., Iwamoto Y., Itoh K.
    • Journal Title

      J Immunol. 172

      Pages: 2659-2667

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin.2004

    • Author(s)
      Mine T., Sato, Y.Noguchi M., Sasatomi T., Gohara R., Tsuda N., Tanaka S., Shomura H., Katagiri K., Rikimaru T., Shichijo S., Kamura T., Hashimoto T., Shirouzu K., Yamada A., Todo S., Itoh K., Yamana H.
    • Journal Title

      Cancer Res. 10

      Pages: 929-937

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Identification of peptide vaccinecandidates sharing among HLA-A3+,-A11+,-A31+ and-A33+ cancer patients. Clin.2004

    • Author(s)
      Takedatsu H., Shichijo S., Katagiri K.Sawamizu H., Sata M., Itoh K.
    • Journal Title

      Cancer Res. 10

      Pages: 1112-1120

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte(CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients.2004

    • Author(s)
      Sasada T., Takedatsu H., Azuma K., Koga M., Maeda Y., Shichijo S., Shoumura H., Hirai T., Takabayashi A., Itoh K.
    • Journal Title

      Cancer Res 64

      Pages: 2882-2888

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.2004

    • Author(s)
      Shichijo S., Azuma K., Komatsu N., Ito M., Maeda Y., Ishihara Y., Itoh K.
    • Journal Title

      Clin Cancer Res 10

      Pages: 5828-5836

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Ran, a small GTPase gene, encodes CTL epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.2004

    • Author(s)
      Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K.
    • Journal Title

      Clin.Cancer Res. 10

      Pages: 6695-6702

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte(CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric eancer patients.2004

    • Author(s)
      Sasada T., Itoh, K., et al.
    • Journal Title

      Cancer Res 64

      Pages: 2882-2888

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Identification of peptide vaccine candidates sharing among HLA-A3+, -All+, -A31+, and-A33+ cancer patients.2004

    • Author(s)
      Takedatsu H., Itoh K., et al.
    • Journal Title

      Clip Cancer Res 10

      Pages: 1112-1120

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic Tlymphocyte-directsd tumor-associated antigens of HLA-A2+ colon cancer.2004

    • Author(s)
      Shichijo S., Itoh K., et al.
    • Journal Title

      Clin Cancer Res 10

      Pages: 5828-5836

    • Related Report
      2004 Annual Research Report
  • [Journal Article] In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I turnor peptide.2004

    • Author(s)
      Harada M., Itoh K., et al.
    • Journal Title

      J Immunol 172

      Pages: 2659-2667

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.2004

    • Author(s)
      Takashi M., Itoh K., et al.
    • Journal Title

      Clin Cancer Res 10

      Pages: 929-937

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B 4601-restricted and tumor cell-reactive CTLs at tumor site.2003

    • Author(s)
      Azuma K., Itoh, K., et al.
    • Journal Title

      Cancer Res 63

      Pages: 854-858

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.2003

    • Author(s)
      Yamada A., Itoh, K., et al.
    • Journal Title

      Cancer Res 63

      Pages: 2829-2835

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B 4601-restricted and tumor cell-reactive CTLs at tumor site.2003

    • Author(s)
      Azuma K., Shichijo S., Maeda Y., Nakatsura T., Nonaka Y., Fujii T., Koike K., Itoh K.
    • Journal Title

      Cancer Res. 63

      Pages: 854-858

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.2003

    • Author(s)
      Yamada A., Kawano K., Koga M., Takamori S., Nakagawa M., Itoh K.
    • Journal Title

      Cancer Res. 63

      Pages: 2829-2835

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur.2002

    • Author(s)
      Nakatsura T., Senju S., Ito M., Nishimura Y., Itoh K.
    • Journal Title

      J.Immunol. 32

      Pages: 826-836

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.2001

    • Author(s)
      Yamada A., Itoh, K., et al.
    • Journal Title

      Cancer Res. 61

      Pages: 6459-6466

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Molecular basis of T cell-mediated recognition of pancreatic cancer cells.2001

    • Author(s)
      Ito M., Itoh, K., et al.
    • Journal Title

      Cancer Res 61

      Pages: 2038-2046

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.2001

    • Author(s)
      Yamada A., Kawano K., Koga M., Matsumoto T., Itoh K.
    • Journal Title

      Cancer Res. 61

      Pages: 6459-6466

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.2001

    • Author(s)
      Miyagi Y., Imai N., Sasatomi T., Yamada A., Mine T., Katagiri K., Nakagawa M., Muto A., Okouchi S., Isomoto H., Shirouzu K., Yamana H., Itoh K.
    • Journal Title

      Clin.Cancer Res. 7

      Pages: 3950-3962

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Molecular basis of T cell-mediated recognition of pancreatic cancer cells.2001

    • Author(s)
      Ito M., Shichijo S., Tsuda N., Ochi M., Harashima N., Saito N., Itoh K.
    • Journal Title

      Cancer Res. 61

      Pages: 2038-2046

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.2000

    • Author(s)
      Kawano, K., Itoh, K., et al.
    • Journal Title

      Cancer Res 60

      Pages: 3550-3558

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.2000

    • Author(s)
      Kawano, K., Gomi, S., Tanaka, K., Tsuda, N., Kamura, T., Itoh, K., Yamada, A.
    • Journal Title

      Cancer Res. 60

      Pages: 3550-3558

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.2000

    • Author(s)
      Nishizaka, S., Gomi, S., Harada, K., Oizumi, K., Itoh, K., Shichijo, S.
    • Journal Title

      Cancer Res. 60

      Pages: 4830-4837

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL.2000

    • Author(s)
      Nakao, M., Shichijo, S., Imaizumi, T., Inoue, Y., Matsunaga, K., Yamada, A., Kikuchi, M., Tsuda, N., Ohta, K., Takamori, S., Yamana, H., Fujita, H., Itoh, K.
    • Journal Title

      J.Immunol. 164

      Pages: 2565-2574

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Book] Tumor Immunology Series, pp 75-96((Ed.) Stauss H. Kawakami, Parmiani G)2003

    • Author(s)
      Kyogo Itoh., et al.
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 上皮細胞増殖因子受容体(EGFR)由来ペプチド2004

    • Inventor(s)
      伊東 恭悟, 七條 茂樹
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2004-015676
    • Filing Date
      2004-01-23
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] ストレス誘導抗アポトーシス分子(IEX-1)由来ペプチド2004

    • Inventor(s)
      伊東 恭悟
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2004-026691
    • Filing Date
      2004-02-03
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 前立腺関連抗原由来HLA-A24結合ペプチド2004

    • Inventor(s)
      伊東 恭悟, 原田 守
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2004-179311
    • Filing Date
      2004-06-17
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 上皮細胞増殖因子受容体(EGFR)由来 ペプチド2004

    • Inventor(s)
      伊東恭悟, 七條茂樹
    • Industrial Property Rights Holder
      学校法人 久留米大学
    • Industrial Property Number
      2004-015676
    • Filing Date
      2004-01-23
    • Related Report
      2004 Annual Research Report
  • [Patent(Industrial Property Rights)] ストレス誘導抗アポトーシス分子(IEX-1)由来ペプチド2004

    • Inventor(s)
      伊東恭悟
    • Industrial Property Rights Holder
      学校法人 久留米大学
    • Industrial Property Number
      2004-026691
    • Filing Date
      2004-02-03
    • Related Report
      2004 Annual Research Report
  • [Patent(Industrial Property Rights)] 前立腺関連抗原由来HLA-A24結合ペプチド2004

    • Inventor(s)
      伊東恭悟, 原田守
    • Industrial Property Rights Holder
      学校法人 久留米大学
    • Industrial Property Number
      2004-179311
    • Filing Date
      2004-06-17
    • Related Report
      2004 Annual Research Report
  • [Patent(Industrial Property Rights)] CD4 陽性 T 細胞に認識されるペプチド2003

    • Inventor(s)
      伊東恭悟, 原田 守
    • Industrial Property Rights Holder
      伊東恭悟
    • Industrial Property Number
      2003-404911
    • Filing Date
      2003-12-03
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] HER2/neu由来ペプチドおよびその治療上の用途2003

    • Inventor(s)
      伊東 恭悟, 七條 茂樹
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2003-275465
    • Filing Date
      2003
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 副甲状腺ホルモン関連タンパク質のHLA-A24または-A2結合ペプチド2003

    • Inventor(s)
      伊東 恭悟, 原田 守
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2003-408891
    • Filing Date
      2003
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] Zesteホモログ2のエンハンサーのHLA-A24結合ペプチド2003

    • Inventor(s)
      伊東 恭悟, 原田 守
    • Industrial Property Rights Holder
      学校法人久留米大学
    • Industrial Property Number
      2003-408895
    • Filing Date
      2003-12-08
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2002

    • Inventor(s)
      伊東 恭悟, 七條 茂樹
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2002-126764
    • Filing Date
      2002
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2002

    • Inventor(s)
      伊東 恭悟, 山田 亮
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2002-286676
    • Filing Date
      2002
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2001

    • Inventor(s)
      伊東 恭悟, 七條茂樹
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2001-177058
    • Filing Date
      2001
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2001

    • Inventor(s)
      伊東 恭悟, 七條 茂樹
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2001-191974
    • Filing Date
      2001
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2001

    • Inventor(s)
      伊東 恭悟, 七條 茂樹
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2001-333219
    • Filing Date
      2001
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2001

    • Inventor(s)
      伊東 恭悟
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2001-376415
    • Filing Date
      2001
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2000

    • Inventor(s)
      伊東 恭悟
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2000-231814
    • Filing Date
      2000
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Patent(Industrial Property Rights)] 腫瘍抗原2000

    • Inventor(s)
      伊東 恭悟, 山田 亮
    • Industrial Property Rights Holder
      伊東 恭悟
    • Industrial Property Number
      2000-304155
    • Filing Date
      2000
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Publications] Kobayashi K., Itoh K, et al.: "Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prost cancer patients."Cancer Sci. 94. 622-627 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Azuma K., Itoh K, et al.: "Mutated p53 gene encodes a non-mutated epitope recognized by HLA-B4601-restritced and tumor-reactive CTLs at tumor site."Cancer Res.. 63. 854-858 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Koga M., Itoh K, et al.: "Identification of ribosomal proteins S2 and L10a as tumor antigensrecognized by HLA-A26-restricted CTL."Tissue Antigens. 61. 136-145 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Yamada A., Itoh K, et al.: "Gene and peptide analyses of newly defined lung cancer rejection antigens reconized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes."Cancer Res.. 63. 2829-2835 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Noguchi M., Itoh K, et al.: "Induction of cellular and humoral immune responses to tumor cells and peptide in hla-A24 positive hormone-refractory prostate cancer patients by peptide vaccination"The Prostate. 57. 80-92 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kawamoto N., Itoh K, et al.: "IgG reactive to CTL-directed epitopes of self-antigens is eitherr lacking or unbalanced in atopic dermatitis patients."Tissue Antigen. 62. 352-361 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Azuma K., Itoh K., et al.: "Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients."Br.J.Cancer. 89. 1079-1085 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Harada M., Itoh K., et al.: "Target molecules in specific immunotherapy against prostate cancer."Int.J.Clin.Oncol. 8. 193-199 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Mine T., Itoh K., et al.: "Immunological evaluation of CTL precursor-oriented vaccines for advand lung cancer patients."Cancer Sci.. 94. 548-556 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Sato Y., Itoh K., et al.: "Immunological evaluation of peptide vaccination for patients with gast cancer based on pre-existing cellular response to peptide."Cancer Sci.. 94. 802-808 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Shichijo S., Itoh K., et al.: "Identification of two novel tumor-associated antigens recognized HLA-B46-restricted cytotoxic T lymphocytes."Int.J.Mol.Med.. 12. 895-902 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Ohkouchi S., Itoh K., et al.: "Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region : a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients."Eur.J.Immunol. 33. 2964-2973 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Tanaka S., Itoh K, et al.: "Peptide vaccination for patients with melanoma and other types of cancer bas on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery."J.Immunother.. 26. 357-366 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Harada M., Itoh K, et al.: "Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients"The prostate. 57. 152-159 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Noguchi M., Itoh K, et al.: "Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer."Cancer Sci.. 95. 77-84 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Takedatsu H., Itoh K, et al.: "Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients. International"Int.J.Oncol.. 24. 337-347 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Tsuda N., Itoh K, et al.: "Vaccination with pre designated or evidence-based peptides for patients with recurrent gynecologic cancers."J Immunother. 27. 60-72 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Harada M., Itoh K, et al.: "In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD T cells reactive to a class I tumor peptides."J Immunol. 172. 2659-2667 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kyogo Itoh: "Tumor Immunology Series volume III"Drs.Kawakami and Parmiani (harwood academic publishers)(in press). (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] Sasatomi T, Itoh K., et al.: "Expression of Tumor Rejection Antigens in Colorectal Carcinomas"Cancer. 94. 1636-1641 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Suzuki N., Itou K., et al.: "Detection of peptide-specific Cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer"Int. J. Cancer. 98. 45-50 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Tanaka K., Itoh K., et al.: "Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients"Jpn. J. Cancer Res.. 98. 198-208 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Yutani S., Itoh K., et al.: "Elevation of serum MAGE-4 protein levels and prediction of hepatocellular carcinogenesis in patients with liver cirrhosis"Jpn. J. Cancer Res.. 93. 453-458 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakatsura R., Itoh K., et al.: "Cellular and humoral immune responses to a human pancreatic cancer antigen, CLP, originally defined by the SEREX method"Eur. J. Immunology. 32. 826-836 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Hida N., Itoh K., et al.: "A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation"Cancer Immunol. Immunother.. 51. 219-228 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Komatsu N., Itoh K., et al.: "Measurement of interferon-γ by high-throughput fluorometric microvolume assay technology system"J. Immunological Methods. 263. 169-176 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Ohkouchi S., Itoh K., et al.: "Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals"Tissue Antigens. 59. 259-272 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Maeda Y., Itoh K., et al.: "Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restriceted and tumor-specific CTLs in the majority of gastrointestinal cancer patients"Int. J. Cancer. 99. 409-417 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Gohara R., Itoh K., et al.: "Phase I Clinical Study of Cyclophilin B Peptide Vaccine for patients with Lung Cancer"J. Immuotherapy. 25. 439-444 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Maeda Y., Itoh K., et al.: "Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients"Br. J. Cancer. 87. 796-804 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nonaka Y., Itoh K., et al.: "Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes form patients with brain tumors"Tissue Antigen. 60. 319-327 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Tsuda N., Itoh K., et al.: "UDP-Gal: β GlcNAc β1,3-galactosyltransferase, polypeptide 3 (GALT3) is a tumor antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumor"Br. J. Cancer. 87. 1006-1012 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Azuma K., Itoh K., et al.: "Mutated p53 gene encodes a non-mutated epitope recognized by HLA-B4601-restritced and tumor-reactive CTLs at tumor site"Tissue Antigens. 63. 854-858 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Koga M., Itoh K., et al.: "Identification of ribosomal proteins S2 and L10a as tumor antigensrecognized by HLA-A26-restricted CTL"Tissue Antigens. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Yamada A., Itoh K., et al.: "Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes"Cancer Res.. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Noguchi M., Itho K., et al.: "Induction of cellular and humoral immune responses to tumor cells and peptide in hla-A24 positive hormone-refractory prostate cancer patients by peptide vaccination"The Prostate. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kawamoto N., Itoh K., et al.: "IgG reactive to CTL-directed epitopes of self-antigens is eitherr lacking or unbalanced in atopic dermatitis patients"Tissue Antigen. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kyogo Itoh: "Tumor Immunology Series volume III"Drs. kawakami and Parmiani (harwood academic publishers)(In press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Nakatsura, R: "Cellular and humoral immune responses to a human pancreatic cancer antigen, CLP, originally defined by the SEREX method"Eur. J. Immunology. (in press). (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] Miyagi, Y: "Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides"Clin. Can. Res.. 7. 3950-3962 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Suzuki, N.: "Detection of peptide-specific Cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer"Int. J. Cancer. (in press). (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Yamada, A.: "Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes"Cancer Res.. 61. 6459-6466 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Imai, N.: "Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases"Int. J. Cancer. 94. 237-242 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Inoue, Y: "Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide"J. Urol.. 166. 1508-1513 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Harada, K.: "Binding of a SART3 tumor-rejection antigen to a pre-mRNA splicing activation factor RNPS1 : a possible regulation of splicing by a complex formation"Int. J. Cancer. 93. 623-629 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Ito, M.: "Molecular basis of T cell-mediated recognition of pancreatic cancer cells"Cancer Res.. 61. 2038-2046 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Suefuji, Y.: "Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients"British J. Cancer. 84. 915-919 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Harashima, N.: "Recognition of the Lck tyrosine kinase as a tumor antigen by T cells of metastatic cancer patients"Eur. J. Immunology. 31. 323-332 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kyogo Itoh: "Tumor Immunology Series volume III"Drs. Kawakami and Parmiani (harwood academic publishers)(in press). (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] Ito,M.: "Molecular basis of T cell-mediated recognition of pancreatic cancer cells."Cancer Research. 61(6). (2001)

    • Related Report
      2000 Annual Research Report
  • [Publications] .Nishizaka,S.: "A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma"Cancer Research. 60(17). 4830-4837 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Kawano,K.: "Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer"Cancer Research. 60(13). 3550-3558 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Nakao,M.: "Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL."Journal of Immunology. 164(5). 2565-2574 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Shinohara,H.: "Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation"Cancer Research. 60(6). 1766-1772 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Nakayama,M.: "Involvement of TWEAK in IFN-γ-stimulated monocyte cytotoxicity."Journal of Experimental Medicine. 192(9). 1373-1379 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 伊東恭悟: "Cell Therapy"Springer. 13 (2000)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2018-03-28  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi